Technosphere insulin in the treatment of Type 1 diabetes mellitus: A systematic review and meta-analysis

被引：0

作者：

Dos Santos, Vitoria Karoline Justino ^{[1
]}

Prado, Marcelo Lucas De Lima ^{[2
]}

Da Silva, Gabriela Simoes Noel ^{[1
,2
]}

Aragao, Iapunira Catarina Sant'anna ^{[3
]}

Aragao, Felipe Matheus Sant'anna ^{[4
]}

Dos Santos, Vitor Henrique Justino ^{[5
]}

Hespanhol, Larissa Calixto ^{[6
]}

De Menezes, Vanessa Lins ^{[7
]}

Reis, Francisco Prado ^{[8
]}

Aragao, Jose Aderval ^{[2
]}

机构：

[1] Hosp Ipiranga, Sao Paulo, SP, Brazil

[2] Univ Fed Sergipe, Sao Cristovao, SE, Brazil

[3] Hosp Municipal Munir Rafful, Volta Redonda, RJ, Brazil

[4] Fac Med Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, SP, Brazil

[5] Univ Anhembi Morumbi, Sao Jose Dos Campos, SP, Brazil

[6] Univ Fed Campina Grande, Campina Grande, PB, Brazil

[7] Univ Sao Paulo, Sao Paulo, SP, Brazil

[8] Univ Tiradentes, Aracaju, SE, Brazil

来源：

JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2025年 / 39卷 / 09期

关键词：

Diabetes mellitus; Insulin; Short-acting; Inhalation; Hypoglycemia; BODY-MASS INDEX; SEVERE HYPOGLYCEMIA; GLYCEMIC CONTROL; ASSOCIATION; IMPAIRMENT;

D O I：

10.1016/j.jdiacomp.2025.109108

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims: Conduct a systematic review and meta-analysis comparing Technosphere Insulin and traditional ultra-rapid insulin in T1DM. Methods: Researchers conducted a systematic search on databases to identify randomized controlled trials (RCTs) comparing two insulin regimens-TI and RAI -in patients with type 1 diabetes mellitus (T1DM). The outcomes of interest included changes in HbA1c levels, body weight, and rates of overall and severe hypoglycemia. Results: Four RCTs were included. There was no significant difference between groups on change in HbA1c (MD 0.04; 95 % CI - 0.19-0.27; p = 0.74; I2 = 0 %). In terms of body weight change, the TI group exhibited significantly less (MD -1.05; 95 % CI -1.63 to -0.46; p = 0.0005; I2 = 0 %) compared to the RAI group. Adverse events such as overall hypoglycemia (RR -0.97; 95 % CI 0.94-1.01; p = 0.24; I2 = 26 %) and severe hypoglycemia (RR 0.63; 95 % CI 0.46-0.87; p = 0.005; I2 = 0 %), were significantly more frequent in the RAI group. Conclusions: The use of Technosphere Insulin (TI) in T1DM patients did not show a difference in HbA1c, suggesting that TI may offer advantages in weight stability and a lower incidence of hypoglycemic events compared to rapid-acting insulin (RAI).

引用

页数：9

共 32 条

[1] Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study [J].